臨床泌尿器科64巻10号

2010年09月発行

綜説

前立腺肥大症の薬物治療―5α還元酵素阻害薬の役割

著者： 酒井英樹¹

所属機関： ¹長崎大学大学院医歯薬学総合研究科腎泌尿器病態学分野

ページ範囲：P.711 - P.718

文献概要

要旨　前立腺肥大症治療薬として，本邦で初めての5α還元酵素阻害薬であるデュタステリドが2009年9月から使用可能となった。デュタステリドは前立腺を25～30％縮小させることで臨床効果を発揮する。海外で行われた5α還元酵素阻害薬の大規模臨床試験から，前立腺肥大症は進行性の疾患であり，その危険因子は大きな前立腺と高いPSA値であることが明らかとなった。また，大きな前立腺肥大症に対して，5α還元酵素阻害薬とα₁遮断薬の併用療法がすみやかな効果発現とともに長期間にわたる進行抑制効果をもたらすことが示され，本邦でも手術を含めた前立腺肥大症の治療体系が変わる可能性がある。

参考文献

1）Russell DW and Wilson JD：Steroid 5 alpha-reductase：two genes/two enzymes. Annu Rev Biochem 63：25-61, 1994

2）Sawaya ME and Price VH：Different levels of 5 alpha-reductase type Ⅰ and Ⅱ, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109：296-300, 1997

3）Thiboutot D, Harris G, Iles V, et al：Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 105：209-214, 1995

4）McConnell JD, Bruskewitz R, Walsh PC, et al：The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338：557-563, 1998

5）Roehrborn CG, Boyle P, Nickel JC, et al：Efficacy and safety of dual inhibitor of 5-alpha reductase types 1 and 2（dutasteride）in men with benign prostatic hyperplasia（BPH）. Urology 60：434-441, 2002

6）Clark RV, Hermann DJ, Cunningham GR, et al：Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 89：2179-2184, 2004

7）Gormley GJ, Stoner E, Bruskewitz RC, et al：The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327：1185-1191, 1992

8）The Finasteride Study Group：Finasteride（MK-906）in the treatment of benign prostatic hyperplasia. Prostate 22：291-299, 1993

9）Nickel JC, Fradet Y, Boake RC, et al：Efficacy and safety of finasteride therapy for benign prostatic hyperplasia：results of a 2-year randomized controlled trial（the PROSPECT study）. PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 155：1251-1259, 1996

10）Hudson PB, Boake R, Trachtenberg J, et al：Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. Urology 53：690-695, 1999

11）斉藤　泰，酒井英樹，折笠精一，他：前立腺肥大症に対するフィナステリド（MK-906）長期投与の臨床的検討．西日泌尿 57：310-319，1995．

12）阿曽佳郎，本間之夫，熊本悦明，他：5α-Reductase阻害剤MK-906の前立腺肥大症に対する臨床第Ⅲ相試験―酢酸クロルマジノン徐放剤を対照薬とする二重盲検群間比較試験．泌尿器外科 8：237-256，1995

13）Roehrborn CG, Boyle P, Nickel JC, et al：Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2（dutasteride）in men with benign prostatic hyperplasia. Urology 60：434-441, 2002

14）Debruyne F, Barkin J, van Erps P, et al：Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46：488-494, 2004

15）塚本泰司，遠藤之洋，成田道郎：日本人男性の前立腺肥大症に対するデュタステリドの至適用量の検討―ランダム化，二重盲検，プラセボ対照，並行群間，用量反応試験．泌尿器科紀要 55：209-214，2009

16）Tsukamoto T, Endo Y and Narita M：Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol 16：745-750, 2009

17）Kirby RS, Roehrborn C, Boyle P, et al：Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia：the Prospective European Doxazosin and Combination Therapy（PREDICT）trial. Urology 61：119-126, 2003

18）Lepor H, Williford WO, Barry MJ, et al：The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335：533-539, 1996

19）McConnell JD, Roehrborn CG, Bautista OM, et al：The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349：2387-2398, 2003

20）Lowe FC：Patient Risk Profiles for Progression of Lower UrinaryTract Symptoms Suggestive of Benign Prostatic Hyperplasia（LUTS/BPH）. Eur Urol Suppl 3：7-11, 2004

21）Crawford ED, Wilson SS, McConnell JD, et al：Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175：1422-1427, 2006

22）Roehrborn CG：Alfuzosin 10mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention：results of a 2-year placebo-controlled study. BJU Int 97：734-741, 2006

23）Siami P, Roehrborn CG, Barkin J, et al：Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement：the CombAT（Combination of Avodart and Tamsulosin）trial rationale and study design. Contemp Clin Trials 28：770-779, 2007

24）Roehrborn CG, Siami P, Barkin J, et al：The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement：2-year results from the CombAT study. J Urol 179：616-621, 2008

25）Roehrborn CG, Siami P, Barkin J, et al：The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia：4-year results from the CombAT study. Eur Urol 57：123-131, 2010

26）Becher E, Roehrborn CG, Siami P, et al：The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement：2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 12：369-374, 2009

27）Barkin J, Roehrborn CG, Siami P, et al：Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia：2-year data from the CombAT trial. BJU Int 103：919-926, 2009

28）Chung BH, Roehrborn CG, Siami P, et al：Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study：2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 12：152-159, 2009

29）Roehrborn CG, Siami P, Barkin J, et al：The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate：2-year data from the CombAT study. Eur Urol 55：461-471, 2009

30）Baldwin KC, Ginsberg PC, Roehrborn CG, et al：Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 58：203-209, 2001

31）Barkin J, Guimarães M, Jacobi G, et al：Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 44：461-466, 2003

32）Andriole GL, Marberger M, Roehrborn CG：Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 175：1657-1662, 2006